TrialVERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
Trial details
- Registry ID
- NCT04842747
- Phase
- Phase 3
VERU
Veru Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
6Trials in this database
4Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceEfficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
Trial details
- Registry ID
- NCT04844749
- Phase
- Phase 3
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer
Trial details
- Registry ID
- NCT04869943
- Phase
- Phase 3
Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer
Trial details
- Registry ID
- NCT05065411
- Phase
- Phase 3
Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt
Trial details
- Registry ID
- NCT06282458
- Phase
- Phase 2
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
Trial details
- Registry ID
- NCT07446998
- Phase
- Phase 2
Latest recorded trial changes
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
NCT07446998 · Veru Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
200 participants (planned)
+ After
239 participants (actual)
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
NCT07446998 · Veru Inc.
Recruitment status changed
− Before
Not yet recruiting
+ After
Recruiting